MitoCatch: Cell-Type-Targeted Mitochondrial Transplantation Rescues Degeneration

Researchers have developed a new system called MitoCatch designed to deliver healthy mitochondria to specific cell types, offering a potential therapeutic strategy for diseases characterized by mitochondrial dysfunction. The study, published in Nature by Ayupov et al. In 2026, addresses a primary limitation in organelle therapy: the inability to target donor mitochondria to the specific cells affected by disease.

Mitochondria are organelles used by nearly all mammalian cell types to manufacture essential molecules and harvest energy from nutrients. When these organelles malfunction, it can lead to a variety of health conditions, including heart failure, cardiovascular disease, obesity, type 2 diabetes, cancer, and neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases.

The MitoCatch Delivery System

The MitoCatch system utilizes protein binders to link donor mitochondria to the surface of target cells. This targeting is achieved through three different mechanisms: cell-surface-displayed monospecific binders, mitochondrion-displayed monospecific binders, or bispecific binders that link the mitochondria directly to the target cells.

Once the mitochondria are captured by the target cells, they are internalized and exposed to the cytosol. The research demonstrates that these transplanted mitochondria can move and undergo the natural processes of fusion and fission inside the target cells. Researchers are able to tune the efficiency of this delivery by engineering binders with varying affinities.

Applications in Human and Animal Models

The study demonstrated the ability to target mitochondrial transplantation across various cell types in both humans and mice. These include:

• Neurons and retinal cell types
• Cardiac cells
• Endothelial cells
• Immune cells

A significant focus of the research was on Leber’s hereditary optic neuropathy (LHON), a vision-loss disorder caused by mitochondrial dysfunction. The researchers used MitoCatch to deliver healthy mitochondria to damaged LHON neurons, which resulted in improved neuronal health and survival.

Further evidence of the system’s efficacy was seen in both in vitro tests using neurons from an individual with optic nerve atrophy and in vivo tests involving neuronal injury in mice, where the transplanted mitochondria promoted the survival of damaged neurons.

Context of Organelle Therapy

The delivery of isolated healthy mitochondria to cells with defective function has been proposed as a form of organelle therapy. While this approach has been demonstrated previously in humans, animals, and in vitro settings, existing methods have suffered from low efficiency and a lack of specificity.

By providing a way to target disease-affected cell types specifically, MitoCatch represents a potential strategy for treating organs affected by mitochondrial dysfunction. The ability to ensure that healthy mitochondria reach the specific cells that need them most is critical for increasing the efficacy of such treatments.